SANTA MONICA, Calif. & REDWOOD GUTA, Calif.–(BUSINESS WIRE)- Kite, Kambani yeGiriyedhi (NASDAQ: GILD), uye Arcellx, Inc. (NASDAQ: ACLX), nhasi yakazivisa kuvharwa kwemakambani akaziviswa kare pasi rose. Kushandirapamwe kwehunyanzvi kubatanidza uye kutengeserana neArcellx inotungamira yekupedzisira-chikamu chechigadzirwa, CART-ddBCMA, yekurapa varwere vane kudzokazve kana refractory multiple myeloma. Multiple myeloma chirwere chisingarapike kuvarwere vazhinji uye chinodiwa chinoramba chiripo chekurapa kunoshanda, kwakachengeteka uye kunowanikwa zvakanyanya.
Parizvino iri kuferefetwa muchikamu chechipiri chekuedza kwakakosha, CART-ddBCMA ndiyo Arcellx's T-cell therapy inoshandisa kambani inovhuvhu synthetic binder, iyo D-Domain. Kite neArcellx vachabatana mberi nekutengesa CART-ddBCMA asset muUS, uye Kite ichatengesa chigadzirwa kunze kweUS.
CAR T-Cell kurapa iri pakati pekurapa kunobudirira kwemamwe marudzi egomarara reropa. Kune anopfuura 750 arikuenderera mberi kliniki miedzo in CAR T-Cell kurapa muChina parizvino. Varwere vanoda kunyoresa vanogona kubata CancerFax runhare rwekubatsira murwere paWhatsApp + 91 96 1588 1588 kana email ku info@cancerfax.com.
Pamusoro peArcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory akawanda myeloma (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, initiated in the fourth quarter of 2022.
About Kite
Kite, Kambani yeGiriyedhi, ikambani yepasi rose biopharmaceutical yakavakirwa muSanta Monica, California, yakatarisana nesero kurapwa kurapa uye kurapa cancer. Semutungamiri wepasi rose wekurapa maseru, Kite akarapa varwere vazhinji neCAR T-cell therapy kupfuura chero imwe kambani. Kite ine yakakura kwazvo-mukati-mumba cell therapy yekugadzira network pasirese, inotenderera process process, kugadzira vector, kiriniki kuyedzwa kwekupa, uye kushambadzira chigadzirwa kugadzira.
NezveGiriyedhi Sayenzi
Giriyedhi Sayenzi, Inc. ikambani yebiopharmaceutical yakatsvaga uye yakawana budiriro mukurapa kweanopfuura makumi matatu emakore, nechinangwa chekugadzira nyika ine hutano kune vese vanhu. Kambani iyi yakazvipira kusimudzira mishonga yekudzivirira nekurapa zvirwere zvinouraya, zvinosanganisira HIV, viral hepatitis negomarara. Gilead inoshanda munyika dzinopfuura 35 munyika yose, ine dzimbahwe muFoster City, California. Sainzi yeGiriyedhi yakawana Kite muna 2017.
